FDA Approval of XPO1 Inhibitor Compound

  • Katrina Williams
  • June 24, 2020

Karyopharm Therapeutics Inc. is proud to announce the FDA approval of their lead XPO1 inhibitor compound to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). To learn more about this recent approval, please see the full press release here. (For XPOVIO®(selinexor) full Prescribing Information please visit: XPOVIO Full Prescribing Information.)

© 2020 FLASCO | Premium Website Design by The HDG

FLASCO